Nabriva Therapeutics plc provided revenue guidance for the fourth quarter of 2021. For the period, The company anticipates reporting that total revenue to grow at a mid-to-high single digit percentage as compare to third quarter of 2021's reported total revenue of $8.9 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2023 | Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
2023 | Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 3 | |
+17.15% | 123B | |
+13.53% | 107B | |
-6.15% | 24.01B | |
+1.31% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-12.60% | 16.23B | |
+2.41% | 13.43B | |
+23.27% | 11.32B |
- Stock Market
- Equities
- NBRVF Stock
- News Nabriva Therapeutics plc
- Nabriva Therapeutics plc Provides revenue Guidance for the Fourth Quarter of 2021